Low-dose Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as an Alternative Therapy for Ovarian Cancer in an Octogenarian Patient

被引:0
作者
Giger-Pabst, Urs [1 ]
Solass, Wiebke [3 ]
Buerkle, Bernd [2 ]
Reymond, Marc-Andre [1 ]
Tempfer, Clemens B. [2 ]
机构
[1] Ruhr Univ Bochum, Dept Surg, Bochum, Germany
[2] Ruhr Univ Bochum, Dept Obstet & Gynecol, Bochum, Germany
[3] Hannover Med Sch, Inst Pathol, Hannover, Germany
关键词
Ovarian cancer; quality of life; antineoplastic agents; adverse effects; intraperitoneal chemotherapy; peritoneal carcinomatosis; octogenarian; high pressure; QUALITY-OF-LIFE; PERITONEAL CARCINOMATOSIS; FEASIBILITY; CISPLATIN; WOMEN;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Octogenarians with ovarian cancer limited to the abdomen may not be willing or able to undergo systemic chemotherapy. Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin is a form of intra-abdominal chemotherapy which can be applied repeatedly and potentially prevents from the systemic side-effects of chemotherapy. Case Report: We present the case of an 84-year-old woman with laparoscopically and histologically confirmed ovarian cancer who refused to undergo systemic chemotherapy. She was treated with eight courses q 28-104 days of low-dose PIPAC with cisplatin at 7.5 mg/m(2) and doxorubicin at 1.5 mg/m(2) at 12 mmHg and 37 degrees C for 30 min. Objective tumor response was noted, defined as tumor regression on histology, and stable disease noted by peritoneal carcinomatosis index on repeated video-laparoscopy and abdominal computed tomographic scan. The treatment was well-tolerated with no Common Terminology Criteria for Adverse Events (CTCAE) CTCAE >2. With a follow-up of 15 months, the patient is alive and clinically stable. The quality of life measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 demonstrated improvement over 5-6 months (global physical score, global health score, global quality of live) without cumulative increase of gastrointestinal toxicity. Conclusion: Low-dose PIPAC is a new form of intra peritoneal chemotherapy which may be applied repeatedly in octogenarian patients. PIPAC may be an alternative and well-tolerated treatment for selected octogenarian patients with ovarian cancer limited to the abdomen who cannot be treated with systemic chemotherapy.
引用
收藏
页码:2309 / 2314
页数:6
相关论文
共 50 条
  • [31] Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study
    Tempfer, Clemens B.
    Winnekendonk, Guido
    Solass, Wiebke
    Horvat, Reinhard
    Giger-Pabst, Urs
    Zieren, Juergen
    Rezniczek, Guenther A.
    Reymond, Marc-Andre
    GYNECOLOGIC ONCOLOGY, 2015, 137 (02) : 223 - 228
  • [32] Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
    Odendahl, K.
    Solass, W.
    Demtroeder, C.
    Giger-Pabst, U.
    Zieren, J.
    Tempfer, C.
    Reymond, M. A.
    EJSO, 2015, 41 (10): : 1379 - 1385
  • [33] Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor: A Single-Institution Experience (ID: PARROT Trial)
    Vizzielli, Giuseppe
    Giudice, Maria Teresa
    Nardelli, Federica
    Costantini, Barbara
    Salutari, Vanda
    Inzani, Frediano Socrate
    Zannoni, Gian Franco
    Chiantera, Vito
    Di Giorgio, Andrea
    Pacelli, Fabio
    Fagotti, Anna
    Scambia, Giovanni
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (03) : 1523 - 1524
  • [34] Pressurized intraperitoneal aerosol chemotherapy (PIPAC): updated systematic review using the IDEAL framework
    Baggaley, Alice E.
    Lafaurie, Guillaume B. R. C.
    Tate, Sophia J.
    Boshier, Piers R.
    Case, Amy
    Prosser, Susan
    Torkington, Jared
    Jones, Sadie E. F.
    Gwynne, Sarah H.
    Peters, Christopher J.
    BRITISH JOURNAL OF SURGERY, 2023, 110 (01) : 10 - 18
  • [35] Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2)
    Khomyakov, Vladimir
    Ryabov, Andrey
    Ivanov, Andrey
    Bolotina, Larisa
    Utkina, Anna
    Volchenko, Nadezhda
    Kaprin, Andrey
    PLEURA AND PERITONEUM, 2016, 1 (03) : 159 - 166
  • [36] Response Evaluation in Patients with Peritoneal Metastasis Treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
    Roensholdt, Signe
    Detlefsen, Sonke
    Mortensen, Michael Bau
    Graversen, Martin
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
  • [37] Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: A multicenter study
    Sgarbura, Olivia
    Hubner, Martin
    Alyami, Mohammad
    Eveno, Clarisse
    Gagniere, Johan
    Pache, Basile
    Pocard, Marc
    Bakrin, Naoual
    Quenet, Francois
    EJSO, 2019, 45 (12): : 2386 - 2391
  • [38] Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma
    Giger-Pabst, Urs
    Demtroeder, Cedric
    Falkenstein, Thomas A.
    Ouaissi, Mehdi
    Goetze, Thorsten O.
    Rezniczek, Guenther A.
    Tempfer, Clemens B.
    BMC CANCER, 2018, 18
  • [39] Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: Preliminary clinical experience
    Tempfer, Clemens B.
    Celik, Ilknur
    Solass, Wiebke
    Buerkle, Bernd
    Pabst, Urs G.
    Zieren, Juergen
    Strumberg, Dirk
    Reymond, Marc-Andre
    GYNECOLOGIC ONCOLOGY, 2014, 132 (02) : 307 - 311
  • [40] Exploring the Spatial Drug Distribution Pattern of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
    Khosrawipour, Veria
    Khosrawipour, Tanja
    Diaz-Carballo, David
    Foerster, Eckart
    Zieren, Juergen
    Giger-Pabst, Urs
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (04) : 1220 - 1224